Table 6.

Antiproliferative Activity of Selected Analogs in Cell Lines with Truncated APC

Cpd.	IC50 ± (nM)a			CLipE
	DLD-1	HT-29	CTRPA A1309b
6	63 ± 5.6	53 ± 2.3	122±6.5	6.68
22	4.8 ± 0.5	2±0.1	3.8 ± 0.7	6.86
29	3.2 ± 0.06	1.2 ± 0.07	6.9±0.8	7.02
30	3 ± 0.25	3 ± 0.05	2.8 ±0.03	7.04
32	4.5 ± 0.2	4±0.1	10.5 ± 0.3	7.94
33	2 ± 0.006	2 ± 0.004	0.7 ± 0.02	7.37
38	0.6 ± 0.02	0.5±0.1	0.8 ± 0.03	6.75
40	2.9 ± 0.34	2.2 ± 0.06	8.2±0.63	6.63
45	5 ± 0.07	4 ± 0.02	9.6 ± 0.3	5.37
46	3 ± 0.23	2.2±0.3	3.4 ± 0.7	6.25
47	0.03 ± 0.0001	0.9 ± 0.08	0.04 ± 0.002	8.32
48	2 ± 0.05	1.1 ± 0.04	3.2 ± 0.4	6.26
49	0.6 ± 0.01	0.45 ± 0.01	0.7 ± 0.05	6.79
51	0.96 ± 0.002	0.74 ± 0.03	1.2 ± 0.06	6.67
60	5 ± 0.06	6 ± 0.07	10.2 ± 0.8	5.81
61	2 ± 0.3	2 ± 0.07	1.6 ±0.3	6.36
81	1.6 ± 0.03	1.5 ± 0.03	3.4 ± 0.3	8.17
85	1.2 ± 0.03	0.8 ± 0.03	1.5 ±0.08	6.14
87	0.65 ± 0.002	0.34 ± 0.02	0.94 ±0.01	7.50
92	0.2 ± 0.03	0.12 ± 0.05	0.9±0.07	8.15
96	3 ± 0.04	2.1±0.07	3.4 ± 0.8	5.31
98	0.3 ± 0.002	0.2 ± 0.001	0.6 ± 0.003	6.69
108	3.5 ± 0.03	3 ± 0.2	4.3 ± 0.1	4.70

^aIC₅₀ values represent the half maximal (50%) inhibitory concentration as determined in the CellTiter-Glo^® (Promega) assay. Error represents SD (n = 3). All compounds were inactive when counter-screened against the HCT116 cell line with wild-type APC status (IC₅₀ > 5 μM).

^bAll compounds were inactive when counter-screened against the isogenic CTRPA cell line with wild-type APC status (IC₅₀ > 5 μM).